Emergence Therapeutics AG. (9/6/22). "Press Release: Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal". Amsterdam & Duisburg.

	Organisation	Synaffix B.V.
	Group	Lonza (Group)
	Product	GlycoConnect™ site-specific antibody-conjugation technology
	Product 2	HydraSpace™ ADC-enhancing spacer
	Person	Elands, Jacobus P. M. (Jack) (Emergence Therapeutics 202006 CEO + Blink Biomedical 201510– CEO before Amakem CEO)
	Person 2	van de Sande, Peter (Synaffix 201904 CEO)

> Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and e xatecan-based SYNtecan E™ linker-payload)

> Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline

> Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties on commercial sales

Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload.

Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at
signature, with the option to expand the collaboration to additional targets. The agreement is the result of positive proof of concept data following a successful initial discovery research collaboration between the companies.

Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Jack Elands, Chief Executive Officer of Emergence Therapeutics, commented: “This transaction demonstrates our commitment to the development of our pipeline of first-in-class and/or best-in- class ADCs. Beyond our lead program ETx-22, a next generation Nectin-4 ADC, we are actively advancing further programs to develop treatments for high unmet-need cancers. We are impressed with the Synaffix technology and are pleased to select it as a key component to accelerate our
pipeline of ADCs.”

Peter van de Sande, Chief Executive Officer of Synaffix, said: “This marks an important milestone for Synaffix as this is the 10 th ADC developer who has licensed our innovative ADC technology to develop proprietary ADCs for their own pipeline. By consolidating all essential technologies within Synaffix, we have repeatedly enabled the development of best-in-class and first-in-class ADCs under a single technology license agreement. We are thrilled that Emergence has selected Synaffix as its long-term ADC technology partner and look forward to working closely with Emergence as they build out their portfolio of ADC candidates.”

-ENDS-

For more information, please contact:

Synaffix B.V.
Anthony DeBoer
Vice President, Business Development
bd@synaffix.com

Optimum Strategic Communications
Hollie Vile, Eleanor Cooper
+44 (0) 208 078 4357
Synaffix@optimumcomms.com

Emergence Therapeutics AG
Dr. Jack Elands, Chief Executive Officer
Tel: +33 6 38 35 70 08

Consilium Strategic Communications
Chris Gardner, Maya Bennison
Email: Emergence@consilium-comms.com
Tel: +44 (0)20 3709 5813

Notes to Editors

About Synaffix B.V.

Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and HydraSpace™
technology, the toxSYN™ linker-payload platform rounds out a fully complementary technology platform that enables any company with an antibody to develop proprietary best-in-class ADC
products under a single license from Synaffix.

The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix’ technology provide end-to-end
protection of the manufacturing technology as well as the resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab and Macrogenics.

Synaffix is backed by a top tier, European, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

For more information, please visit www.synaffix.com.

About Emergence Therapeutics AG

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Emergence Therapeutics is also actively developing a pipeline of further first- or best-in-class ADCs driven by therapeutic need. Emergence is supported by a network of world-leading experts in immuno-oncology and a leading international investor syndicate. Emergence Therapeutics AG is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit:
www.emergencetx.com

About The Synaffix ADC Platform Technology

Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.

GlycoConnect™ is a conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats. HydraSpace™ is a compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads. toxSYN™ is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E™ and SYNeamicin G™, among other linker-payloads.

The combination of these three technologies provides developers with a “one stop” and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.

Record changed: 2023-06-05